AIM ImmunoTech Files Q3 2024 10-Q

TL;DR

AIM ImmunoTech Q3 10-Q filed. Financials and stock details updated.

AI Summary

AIM ImmunoTech Inc. filed its Q3 10-Q report for the period ending September 30, 2024. The company, formerly known as Hemispherx Biopharma Inc., is involved in biological products. Key financial details and stock information are presented in the filing.

Why It Matters

This filing provides investors with the latest financial performance and operational updates for AIM ImmunoTech, crucial for understanding the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — Biotech companies often carry higher risk due to the nature of drug development and regulatory hurdles.

Key Numbers

• 2024-09-30 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
• 2024-11-14 — Filing Date (The date the 10-Q report was officially submitted to the SEC.)

Key Players & Entities

• AIM ImmunoTech Inc. (company) — Filer of the 10-Q report
• Hemispherx Biopharma Inc. (company) — Former name of AIM ImmunoTech Inc.
• 20240930 (date) — End of the reporting period
• 20241114 (date) — Filing date of the report

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share AIM NYSE American Indic
• $273,000 — ember 30, 2024 on equity securities was $273,000. The net losses recognized for the thre
• $59,000 — securities sold during the period were ($59,000). The unrealized gains recognized for t
• $332,000 — 024 on equity securities still held was $332,000. The net gain recognized for the nine-m
• $96,000 — ember 30, 2024 on equity securities was $96,000. The net losses recognized for the nine
• $277,000 — securities sold during the period were ($277,000). The unrealized gains recognized for t
• $373,000 — 024 on equity securities still held was $373,000. Mutual Funds classified as available
• $309,000 — mber 30, 2023 on equity securities was ($309,000). The net losses recognized for the thr
• $42,000 — securities sold during the period were ($42,000). The unrealized losses recognized duri
• $267,000 — 23 on equity securities still held was ($267,000). The net losses recognized for the nin
• $201,000 — mber 30, 2023 on equity securities was ($201,000). The net losses recognized for the nin
• $130,000 — securities sold during the period were ($130,000). The unrealized losses recognized duri
• $71,000 — 23 on equity securities still held was ($71,000). 7 Note 4: Property and Equipment,
• $3,000,000 — tion of long-term debt of approximately $3,000,000 is net of the current portion of debt d
• $397,000 — rtion of debt discount of approximately $397,000 and the current portion of debt origina

Filing Documents

• form10-q.htm (10-Q) — 1348KB
• ex3-1i1.htm (EX-3.1) — 14KB
• ex4-1.htm (EX-4.1) — 1KB
• ex10-15.htm (EX-10.15) — 11KB
• ex31-1.htm (EX-31.1) — 20KB
• ex31-2.htm (EX-31.2) — 20KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• image_001.jpg (GRAPHIC) — 5KB
• ex-a_001.jpg (GRAPHIC) — 170KB
• ex-a_002.jpg (GRAPHIC) — 95KB
• ex-a_003.jpg (GRAPHIC) — 135KB
• ex-a_004.jpg (GRAPHIC) — 154KB
• ex-a_005.jpg (GRAPHIC) — 172KB
• ex-a_006.jpg (GRAPHIC) — 191KB
• ex-a_007.jpg (GRAPHIC) — 84KB
• ex-a_008.jpg (GRAPHIC) — 175KB
• ex-a_009.jpg (GRAPHIC) — 182KB
• ex-a_010.jpg (GRAPHIC) — 165KB
• ex-a_048.jpg (GRAPHIC) — 174KB
• ex-a_049.jpg (GRAPHIC) — 96KB
• ex-a_050.jpg (GRAPHIC) — 189KB
• ex-a_055.jpg (GRAPHIC) — 93KB
• ex-a_056.jpg (GRAPHIC) — 217KB
• ex4-1_001.jpg (GRAPHIC) — 289KB
• 0001493152-24-045971.txt ( ) — 10149KB
• aim-20240930.xsd (EX-101.SCH) — 47KB
• aim-20240930_cal.xml (EX-101.CAL) — 55KB
• aim-20240930_def.xml (EX-101.DEF) — 216KB
• aim-20240930_lab.xml (EX-101.LAB) — 402KB
• aim-20240930_pre.xml (EX-101.PRE) — 303KB
• form10-q_htm.xml (XML) — 1070KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 Commission File Number: 001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Delaware 52-0845822 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 2117 SW Highway 484 , Ocala FL 34473 (Address of principal executive offices) (Zip Code) (352) 448-7797 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.001 per share AIM NYSE American Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No 63,706,446 shares of common stock were outstanding, and no shares of series B preferred stock were outstanding as of November 11, 2024. PART I- FINANCIAL INFORMATION ITEM 1 : Financial Statements AIM IMMUNOTECH INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (in thousands, except for share and per share amounts) (Unaudited September 30, 2024 and Audited December 31, 2023) September 30, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 915 $ 5,439 Marketable securities 6,287 7,631 Funds receivable from New Jersey net operating loss — 1,184 Prepaid expenses and other current assets 368 302 Total current assets 7,570 14,556 Property and equipment, net 117 127 Right of use asset, net 653 697 Patent and trademark rights, net 2,532 2,313 Other assets 2,716 1,688 Total assets $ 13,588 $ 19,381 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 6,264 $ 6,443 Accrued expenses 1,011 1,986 Current portion of operating lease liability 232 223 Current portion of note payable, net 2,593 — Total current liabilities 10,100 8,652 Long-term liabilities: Operating lease liability 437 495 Note payable, net 139 — Total liabilities 10,676 9,147 Commitments and contingencies (Notes 13 and 14) - Stockholders' equity: Series A Junior Participating Preferred Stock, $ 0.001 par value, 4,000,000 and 250,000 shares authorized as of September 30, 2024, and December 31, 2023, respectively: issued and outstanding – none — — Series B Convertible Preferred Stock, stated value $ 1,000 per share, 10,000 shares authorized; no issued and outstanding as of September 30, 2024 and 689 issued and outstanding as December 31, 2023 — 689 Convertible preferred stock, value — 689 Common Stock, $ 0.001 par value, authorized shares - 350,000,000 ; issued and outstanding shares 58,668,647 and 49,102,484 as of September 30, 2024 and December 31, 2023, respectively 59 49 Additional paid-in capital 423,714 419,004 Accumulated deficit ( 420,861 ) ( 409,508 ) Total stockholders' equity 2,912 10,234 Total liabilities and stockholders' equity $ 13,588 $ 19,381 See accompanying notes to consolidated financial statements. 2 AIM IMMUNOTECH INC. AND SUBSIDIARIES Consolidated (in thousands, except share and per share data) (Unaudited) Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Revenues: Clinical treatmen

View Full Filing

View this 10-Q filing on SEC EDGAR